Dr Reddys Laboratories, an integrated global pharmaceutical company, climbed on Wednesday after it launched Fenofibrate capsules, USP 43 mg and 130 mg a therapeutic equivalent generic version of Antara (fenofibrate) capsules, in the US market, approved by the United States Food & Drug Administration (USFDA).

The Antara capsules brand and generic had US sales of approximately USD 74 million MAT for the most recent twelve months ending in February 2014 according to IMS Health.

Shares of the company are trading at Rs 2,581, up Rs 28.3, or 1.11% at the Bombay Stock Exchange (BSE) on Wednesday at 11:48 a.m.

The scrip has touched an intra-day high of Rs 2,585.70 and low of Rs 2,550. The total volume of shares traded at the BSE is 6,807.

In the earlier session, the shares fell 0.01%, or Rs 0.15, at Rs 2,552.70. Currently, the stock is trading down 12.2% from its 52-week high of Rs 2,939.80 and above 37.21% over the 52-week low of Rs 1,881.